NCT06175780招募中1 期
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 189
- 试验地点
- 8
- 主要终点
- Number of patients with dose-limiting toxicity (DLT)
研究概览
简要总结
This dose escalation and dose expansion study is to evaluate and characterize the tolerability, safety, pharmacokinetics and efficacy profile of single agent KY-0118 in Locally Advanced or Metastatic Solid Tumor Patients.
详细描述
For Phase Ia It aims to evaluate the safety, tolerability, pharmacokinetic characteristics, pharmacodynamic effect, immunogenicity in subjects with locally advanced or metastatic solid tumor patients , and determine the appropriate dose of KY-0118.
For Phase Ib it aims is to further evaluate the efficacy, safety, tolerability, pharmacokinetic properties, pharmacodynamic effects and immunogenicity of KY-0118 with appropriate dose groups (approximately 3-5 dose groups) in different Administration manner.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years old and ≤75 years old, male or female;
- •Subjects with a documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic; progression or are intolerant to existing standard therapy or subjects without standard therapy;
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1；Expected survival time≥ 12 weeks;
- •At least one measurable lesion per RECIST 1.1 (without local treatment or progress after local treatment);
- •Adequate organ function;
- •Toxicity from prior anticancer therapy recovered to ≤ grade 1 prior to the first dose of study drugs;
- •Signed informed consent and willingly adherence to the experimental treatment protocol and visit plan.
排除标准
- •Specific anti-tumor treatment prior to use of study treatment;
- •Immunosuppressants or systemic hormone therapy were being used and were not discontinued within 2 weeks prior to enrollment;
- •IL-2 treatment within 6 months prior to the first dose of study drugs;
- •Any immune related adverse events (irAE) that have occurred during previous immunotherapy medication, with a grade of ≥ 3 or leading to termination of immunotherapy;
- •Primary Central Nervous System (CNS) Malignant Tumors or Active CNS Metastasis with Local Treatment Failure;
- •Any severe and/or uncontrolled diseases, including but not limited to: uncontrolled hypertension or pulmonary hypertension or unstable angina; Chronic heart failure; Valve disease; Severe arrhythmia; Had myocardial infarction or bypass or stent surgery within 6 months before screening;
- •History of arteriovenous thromboembolism within 6 months prior to screening；
- •Moderate or severe respiratory distress at rest due to advanced malignant tumors or their complications or severe primary lung diseases；or a current need for continuous oxygen therapy, or a current history of interstitial lung disease (ILD) or pneumonia, severe chronic obstructive pulmonary disease, severe pulmonary insufficiency, symptomatic bronchospasm, etc. ;
- •Uncontrolled bleeding or known tendency to bleed; Patients with chronic Crohn's disease and ulcerative colitis;Patients with hereditary nonpolyposis colorectal cancer or familial adenomatous polyposis syndrome;Patients with a history of intestinal perforation and fistula, but not cured after surgical treatment;Esophagogastric varices;
- •Third space effusion that cannot be controlled by puncture and drainage treatment and require repeated drainage or have obvious symptoms;
- •Patients who require extensive fluid replacement assessed by investigators;
- •Active hepatitis B or active hepatitis C;
- •Active infectious process;
- •A history of immunodeficiency;
- •Autoimmune diseases, including but not limited to systemic lupus erythematosus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Hashimoto's thyroiditis, autoimmune thyroid disease, multiple sclerosis, etc.;
- •Patients with allergic constitution, or known to have a history of allergy to IL-2 or PD-1/PD-L1 drugs or any of their components, or known to have a history of severe allergic reactions to fusion proteins;
- •History of other malignancies within 5 years prior to screening;
- •Surgery (other than diagnostic biopsy) within 4 weeks prior to screening or planned to have surgery during the study period;
- •Had received live vaccine within 4 weeks before the first dose or planned to receive live vaccine during the trial;
- •History of neurological or psychiatric disorders, such as epilepsy, dementia, altered mental status, and poor compliance;
- •History of alcohol or drug abuse within the last 1 year;
- •Women who are pregnant or breastfeeding. Patients unwilling to use a highly effective method of contraception during the study period and for 6 months after receiving the trial drug;
- •Attended other study within 4 weeks prior to screening;
- •Other conditions deemed unsuitable for inclusion by the investigators.
研究组 & 干预措施
KY-0118
Experimental
干预措施: KY-0118 (Drug)
Cohort1: KY-0118
Experimental
干预措施: KY-0118 (Drug)
Cohort2: KY-0118
Experimental
干预措施: KY-0118 (Drug)
结局指标
主要结局
Number of patients with dose-limiting toxicity (DLT)
时间窗: 21 days during the first 3-week cycle
Adverse Event
时间窗: Up to 28 days post last dose
Incidence of untoward medical occurrences (adverse event = AE) in a participant who received study drug. Adverse events will be evaluated by dosing cohort and recorded according to NCI CTCAE Version 5.0.
次要结局
- Ctrough(Up to 7 days post last dose)
- IL-6(Up to 7 days post last dose)
- CL(Up to 7 days post last dose)
- Cmax(Up to 7 days post last dose)
- Tmax(Up to 7 days post last dose)
- T1/2(Up to 7 days post last dose)
- AUC(Up to 7 days post last dose)
- NK cells count(Up to 7 days post last dose)
- TNF-ɑ(Up to 7 days post last dose)
- Progression-free survival (PFS)(Up to 28 days post last dose)
- Duration of response(DOR)(Up to 28 days post last dose)
- Disease control rate (DCR)(Up to 28 days post last dose)
- The incidence of ADA of KY-0118(Up to 7 days post last dose)
- The incidence of NAb of KY-0118(Up to 7 days post last dose)
- PD-1 receptor occupancy rate(Up to 7 days post last dose)
- IL-2 receptor occupancy rate(Up to 7 days post last dose)
- Ki67 phenotype(Up to 7 days post last dose)
- Regulatory t cells（Tregs）(Up to 7 days post last dose)
- CD4+ T lymphocyte count(Up to 7 days post last dose)
- CD8+ T lymphocyte count(Up to 7 days post last dose)
- IFN-γ(Up to 7 days post last dose)
- Granzyme B(Up to 7 days post last dose)
- Perforin(Up to 7 days post last dose)
- Objective response rate (ORR)(Up to 28 days post last dose)
研究者
研究点 (8)
Loading locations...
相似试验
终止
1 期
A Phase I Study of RGT-264 in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT05764915Regor Pharmaceuticals Inc.11
进行中（未招募）
1 期
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid TumorsAdvanced Solid TumorBreast CancerNCT06299124Regor Pharmaceuticals Inc.40
已完成
1 期
A Trial of SHR-7367 in Subjects With Advanced Solid TumorsAdvanced Solid TumorsNCT05740202Shanghai Hengrui Pharmaceutical Co., Ltd.22
进行中（未招募）
1 期
A Study of FDA018-ADC in Patients With Advanced Solid TumorsAdvanced/ Metastatic Solid TumorsNCT05174637Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.78
尚未招募
1 期
AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant TumorsAdvanced Malignant TumorsNCT06691360Akeso87